News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Panel Narrowly Backs New Use of UCB, Inc. (UCBJF.PK)'s Arthritis Drug


7/24/2013 8:02:28 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Belgian pharmaceutical group UCB SA said a committee of the U.S. Food and Drug Administration voted in favour of allowing UCB's arthritis drug Cimzia to be used to treat adults with active axial spondyloarthritis. While the vote was not binding on a final recommendation, it would play a part in the decision to clear the drug for this application in the United States, UCB said.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters

comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES